AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17295586
Drug: Daily dip-evening
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily dip-evening incline cluster smoking patterns
Trial: 17295586
Drug: Daily decline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily decline cluster smoking patterns
Trial: 12891637
Drug: Long-acting opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting opioid therapy for 4 weeks
Trial: 9198464
Drug: aceclofenac 100
RxNorm normalized name: aceclofenac 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aceclofenac 100 mg/12 h
Trial: 9198464
Drug: paracetamol 650
RxNorm normalized name: Paracetamol 650 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paracetamol 650 mg/12 h
Trial: 24858257
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Chinese medicine (CM) and Western medicine intervention termed optimum proposal of integration of disease and syndrome (OPIDS)
Trial: 19573229
Drug: Identifying obstacles
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Identifying obstacles for RTW and formulating solutions for suitable (therapeutic) work with the help of an independent RTW coordinator.
Trial: 15646911
Drug: EMLA (eutectic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA (eutectic mixture of local anesthetics, 2.5% lidocaine and 2.5% prilocaine) cream
Trial: 11158042
Drug: levormeloxifene 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levormeloxifene 1.25 mg/day
Trial: 11158042
Drug: levormeloxifene 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levormeloxifene 5 mg/day
Trial: 11158042
Drug: levormeloxifene 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levormeloxifene 10 mg/day
Trial: 11158042
Drug: levormeloxifene 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levormeloxifene 20 mg/day
Trial: 11158042
Drug: low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low dose HRT (1 mg 17 beta‐estradiol and 0.5 mg norethisterone acetate/day)
Trial: 11158042
Drug: placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (500 mg calcium)
Trial: 11158042
Drug: low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low dose HRT
Trial: 29635632
Drug: Hydromorphone immediate-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone immediate-release tablets at a dose converted at a hydromorphone:morphine ratio of 1:5
Trial: 29635632
Drug: Hydromorphone immediate-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone immediate-release tablets at a dose converted at a hydromorphone:morphine ratio of 1:8
Trial: 25511551
Drug: Daily intravaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intravaginal 0.50% prasterone for 2 weeks followed by twice weekly for 10 weeks
Trial: 21524710
Drug: Banana consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Banana consumption (one medium banana twice a day)
Trial: 21524710
Drug: Banana-flavoured drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Banana-flavoured drink (one cup twice a day)
Trial: 21524710
Drug: Water (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (one cup twice a day)
Trial: 19505388
Drug: Pre-co-seasonal sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-co-seasonal sublingual immunotherapy with modified allergen extract
Trial: 16772806
Drug: Oxycodone/Paracetamol 5/325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone/Paracetamol 5/325 mg and 10/650 mg
Trial: 16772806
Drug: Bromfenac 25
RxNorm normalized name: bromfenac 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromfenac 25 mg and 50 mg
Trial: 15531006
Drug: Valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 80 mg once daily (level 1)
Trial: 15531006
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg once daily (level 1)
Trial: 15531006
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg once daily (level 2)
Trial: 15531006
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg once daily (level 2)
Trial: 15531006
Drug: Hydrochlorothiazide 12.5
RxNorm normalized name: hydrochlorothiazide 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 12.5 mg added (level 3)
Trial: 15531006
Drug: Combined treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatments (Valsartan and Amlodipine)
Trial: 8356997
Drug: nabumetone (1,000‐2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nabumetone (1,000‐2,000 mg/day)
Trial: 8356997
Drug: diclofenac (100‐200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac (100‐200 mg/day)
Trial: 8356997
Drug: naproxen (500‐1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen (500‐1,500 mg/day)
Trial: 28851317
Drug: NaturaLyte® acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaturaLyte® acid concentrate (4 mEq/L acetate)
Trial: 28851317
Drug: GranuFlo® acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GranuFlo® acid concentrate (8 mEq/L acetate)
Trial: 25498218
Drug: Immediate chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate chemotherapy (four cycles of gemcitabine plus cisplatin, high-dose methotrexate, vinblastine, doxorubicin, and cisplatin [high-dose MVAC])
Trial: 25498218
Drug: Deferred chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred chemotherapy (six cycles at relapse)
Trial: 25498218
Drug: Deferred chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred chemotherapy
Trial: 23683266
Drug: 3.6 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 g/d of omega-3 fatty acid (O3A) ethyl esters
Trial: 12839147
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V 500 mg 3 times daily for 10 days
Trial: 7848019
Drug: Twice-daily, low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily, low-molecular-weight heparin
Trial: 2248843
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bupivacaine and lignocaine
Trial: 30422193
Drug: Sedative-hypnotics (intervention)
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedative-hypnotics (intervention)
Trial: 30422193
Drug: Sedative-hypnotics (control)
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedative-hypnotics (control)
Trial: 30422193
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drugs (intervention)
Trial: 30422193
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drugs (control)
Trial: 27375714
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg propofol
Trial: 27375714
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg propofol plus 0.5 mg/kg ketamine
Trial: 26242117
Drug: Celecoxib Capsule
RxNorm normalized name: Celecoxib Capsules
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib Capsule (Control)
Trial: 15657341
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and radiation therapy (37.5 Gy in 16 fractions)
Trial: 10589645
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (warm blankets and/or radiant heat)
Trial: 7847521
Drug: Ceftriaxone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (1 gm daily intravenous)
Trial: 7847521
Drug: Cefazolin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (2 gm three times daily intravenous)
Trial: 1819436
Drug: Combined yellow‐fever‐measles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined yellow‐fever‐measles vaccine
Trial: 1819436
Drug: Yellow‐fever and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow‐fever and measles separate administration
Trial: 31877392
Drug: Infant carrying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant carrying (babywearing) for 1 hour daily for 3 months
Trial: 28466151
Drug: Delay in
RxNorm normalized name: Delayed Release Oral Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delay in antimicrobial therapy.
Trial: 26503395
Drug: Supportive educational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive educational intervention for carers (4 components: initial telephone assessment, tailored resource folder, home visit, ongoing monthly support for 12 months)
Trial: 23813851
Drug: Nurse-coordinated prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-coordinated prevention programme (four outpatient nurse clinic visits focusing on healthy lifestyles, biometric risk factors, and medication adherence)
Trial: 22118755
Drug: Longevinex administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longevinex administered for 3 months (Group A)
Trial: 22118755
Drug: Longevinex administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longevinex administered between 3 and 6 months (Group B)
Trial: 19302901
Drug: Posaconazole 200
RxNorm normalized name: posaconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole 200 mg BID for 7 days
Trial: 19302901
Drug: Posaconazole 400
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole 400 mg BID for 7 days
Trial: 19302901
Drug: Ketoconazole 400
RxNorm normalized name: ketoconazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 400 mg once daily for 7 days
Trial: 19302901
Drug: Midazolam (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (oral 2 mg and IV 0.4 mg) administered with either azole
Trial: 17582178
Drug: Systemic steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic steroids (Methyl prednisolone 0.5 mg/kg/day in two divided doses)
Trial: 17582178
Drug: Nebulized steroids
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized steroids (Budecort 50 mcg/dose twice daily)
Trial: 15449752
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml of 6% hydroxyethylstarch (HES)
Trial: 15449752
Drug: 1000 ml
RxNorm normalized name: TPN Bag 1000 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 ml of 6% hydroxyethylstarch (HES)
Trial: 11343734
Drug: Treatment by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment by primary-care physician
Trial: 11343734
Drug: Treatment by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment by pain specialist
Trial: 11343734
Drug: Overall desire
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall desire for additional treatment
Trial: 9518909
Drug: temazepam 10
RxNorm normalized name: temazepam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: temazepam 10 mg
Trial: 7853442
Drug: Manioc Salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manioc Salt Solution (MSS)
Trial: 7853442
Drug: Pap Salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pap Salt Solution (PSS)
Trial: 7853442
Drug: World Health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: World Health Organization/Oral Rehydration Solution (WHO/ORS)
Trial: 189333
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg ACTH 4-10 subcutaneously
Trial: 31693803
Drug: Tetravalent dengue
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent dengue vaccine (TAK-003)
Trial: 28481726
Drug: RV3-BB vaccine
RxNorm normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RV3-BB vaccine (both schedules)
Trial: 28481726
Drug: RV3-BB vaccine
RxNorm normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RV3-BB vaccine
Trial: 25954737
Drug: Azithromycin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (30 mg/kg, three once-weekly doses)
Trial: 19114797
Drug: Documented ventricular
RxNorm normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Documented ventricular tachycardia (VT) at the time of ICD implant
Trial: 1565758
Drug: placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets (usual sodium)
Trial: 29882841
Drug: 2000 IU
RxNorm normalized name: D 2000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 IU vitamin D₃ daily
Trial: 29882841
Drug: 50,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50,000 IU vitamin D₃ monthly
Trial: 27640797
Drug: Drospirenone and
RxNorm normalized name: drospirenone and estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drospirenone and ethinylestradiol tablets group
Trial: 22684569
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with tyrosine, lecithin, L‐glutamine and 5‐HTP, n=41
Trial: 20170333
Drug: Fixed-dose budesonide/formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose budesonide/formoterol 160/4.5 microg x 2 inhalations (320/9 mug) twice daily
Trial: 20170333
Drug: Fixed-dose fluticasone
RxNorm normalized name: fluticasone Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose fluticasone propionate/salmeterol 250/50 microg twice daily
Trial: 20170333
Drug: Adjustable-dose budesonide/formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjustable-dose budesonide/formoterol (adjustable from 320/9 microg twice daily to 320/9 microg once daily or 640/18 microg twice daily)
Trial: 18693154
Drug: BPO 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPO 10% gel
Trial: 7881965
Drug: Initial cytotoxic
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial cytotoxic or endocrine treatment followed by mastectomy
Trial: 7881965
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Immediate modified radical mastectomy and Initial cytotoxic or endocrine treatment)
Trial: 29474935
Drug: Turbuhaler® M3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turbuhaler® M3 (1.5 mg terbutaline)
Trial: 29474935
Drug: Turbuhaler® M2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turbuhaler® M2 (1.5 mg terbutaline)
Trial: 29474935
Drug: Turbuhaler® M3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turbuhaler® M3 (0.5 mg terbutaline)
Trial: 29474935
Drug: Turbuhaler® M2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turbuhaler® M2 (0.5 mg terbutaline)
Trial: 16330394
Drug: Ethanol (0.97+/‐0.12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.97+/‐0.12 g/kg body weight)
Trial: 2716162
Drug: Sustained-release PPA
RxNorm normalized name: phenylpropanolamine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release PPA hydrochloride 75 mg once per day
Trial: 2716162
Drug: Immediate-release PPA
RxNorm normalized name: phenylpropanolamine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release PPA hydrochloride 25 mg three times per day
Trial: 2716162
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules three times per day
Trial: 28182127
Drug: Metoprolol (23.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (23.75 or 47.5 mg, qd PO, dose escalated with 23.75 mg each time until target heart rate [HR] <70 bpm was achieved)
Trial: 26556275
Drug: Clindamycin, ciprofloxacin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin, ciprofloxacin, amoxicillin, and minocycline
Trial: 23799683
Drug: Self-administered web-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered web-based computer intervention
Trial: 21326107
Drug: Olprinone at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olprinone at 0.2 μg·kg(‐1)·min(‐1)
Trial: 21326107
Drug: Olprinone at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olprinone at 0.4 μg·kg(‐1)·min(‐1)
Trial: 21326107
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0 μg·kg(‐1)·min(‐1))
Trial: 19057445
Drug: Intravenous hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous hydrocortisone 5 mg/kg/day in four divided doses for 7 days
Trial: 17721240
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of propofol (2.5 mg/kg)
Trial: 17721240
Drug: 1-, 2-,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-, 2-, or 3-min infusion of propofol (2.5 mg/kg)
Trial: 11027910
Drug: Gabapentin (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (titrated from 1,200 mg/day to a maximum of 2,400 mg/day)
Trial: 11027910
Drug: Amitriptyline (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (titrated from 30 mg/day to a maximum of 90 mg/day)
Trial: 8450987
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment with antiepileptic drugs (carbamazepine, phenytoin, phenobarbital, or sodium valproate)
Trial: 8450987
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment with the same antiepileptic drugs
Trial: 6115730
Drug: Propranolol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (all doses)
Trial: 28141545
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (1000 mg containing 180 mg EPA and 120 mg DHA)
Trial: 23103775
Drug: Propofol 1
RxNorm normalized name: propofol 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1 mg kg(‐1) (Group P)
Trial: 23103775
Drug: Fentanyl 1
RxNorm normalized name: fentanyl 1.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1 µg kg(‐1) (Group F)
Trial: 17457713
Drug: 3-in-1 femoral
RxNorm normalized name: SUS SCROFA TEMPORAL LOBE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-in-1 femoral nerve block with 40 ml of ropivacaine 0.375% (Group R)
Trial: 17457713
Drug: Morphine loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine loading dose of 2 mg (Group S)
Trial: 12637461
Drug: Tamoxifen plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen plus aminoglutethimide (500 mg/d for the first 2 years)
Trial: 12637461
Drug: Tamoxifen (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (40 mg/d for the first 2 years, then 20 mg/d for 3 years)
Trial: 10925565
Drug: 5 x
RxNorm normalized name: PAD,ABDOMINAL 5 X 9 STERILE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 x 10(‐4)% fentanyl (10‐20 mL) administered epidurally during early first-stage labor (Group A)
Trial: 10925565
Drug: No analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No analgesic during the early first stage of labor (Group B)
Trial: 10925565
Drug: No analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No analgesic during the entire labor course (Group C)
Trial: 6143538
Drug: Betaxolol 20
RxNorm normalized name: betaxolol 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol 20 mg
Trial: 30786187
Drug: Plazomicin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plazomicin (15 mg per kilogram of body weight once daily)
Trial: 27504543
Drug: 20% trichloro‐acetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% trichloro‐acetic acid peel plus 5% topical magnesium ascorbyl phosphate
Trial: 19427744
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (cisplatin 50 mg/m², Days 1 and 8; paclitaxel 175 mg/m² Day 1, every 21 days) followed by concurrent CRT (accelerated-hyperfractionated regimen, 45 Gy, 2 x 1.5 Gy/d, cisplatin 50 mg/m², Days 64 and 71, vinorelbine 20 mg/m², Days 64 and 71)
Trial: 19427744
Drug: Definitive radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Definitive radiotherapy (total dose 65 or 71 Gy, depending on the mean lung dose) with additional concurrent chemotherapy (cisplatin 40 mg/m², Day 85; vinorelbine 15 mg/m², Days 85 and 92)